Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan

Figure 3 The adjusted mean difference in body weight from baseline to 12 wk between placebo and the standard dose of sodium-glucose cotransporter 2 inhibitors. A: 50 mg ipragliflozin in Westerners; B: 50 mg ipragliflozin in Japanese; C: 100 mg canagliflozin in Westerners; D: 10 mg dapagliflozin in Westerners; E: 25 mg empagliflozin in Westerners.